Healthcare Providers and Payers
COVID-19, Flu & RSV Active Infection Test
Who should be tested?
Individuals infected with COVID-19, influenza A/B or RSV often experience similar symptoms of cough, fever, and a runny and/or stuffy nose. Because flu and COVID-19 especially share so many similar symptoms, the CDC advises that patients may need testing to confirm a diagnosis. Patients may also be considered for testing if they have come into contact with someone they know who is infected by the coronavirus or meet criteria established by the CDC.
Sample
Short nasal swab
Where are samples collected?
- At a healthcare provider office, hospital, or other designated testing location under supervision of a healthcare provider.
Getting Tested
Patients can visit a physician's office for testing.
Labcorp Test Number
Physicians have test options:
2019 Novel Coronavirus (COVID-19), NAA 139900
2019 Novel Coronavirus (COVID-19) with Influenza A and Influenza B, NAA 140147
Influenza A, Influenza B and Respiratory Syncytial Virus, NAA 140163
Influenza A and Influenza B, NAA 140165
2019 Novel Coronavirus (COVID-19) with Respiratory Syncytial Virus, NAA 140172
Receiving Results
- As of November 17, 2020, the current average time to deliver results for COVID-19, Flu & RSV combined testing is 1-3 days from the date of specimen pickup.
- Delivered to the ordering physician's EMR or Labcorp Link
Additional Information
- Labcorp COVID-19 Specimen Collection Guide (Illustrated)
- COVID-19 Direct Observed Patient Specimen Collection
- SARS-CoV-2 Specimen Collection Supplies Q&A
- COVID-19 Nucleic Acid Amplification Nasal Swab (Anterior Nares) Collection for Healthcare Providers
- COVID-19 PCR Testing Specimen Collection Grid
- COVID-19 RT-PCR Test (anterior nares) specimen collection instructions (foam swab)
Labcorp’s COVID-19 PCR test has not been FDA cleared or approved, has been authorized by FDA under an Emergency Use Authorization (EUA), and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
COVID-19 Information and Resources
Have a Question?
More Information
Get Started with Labcorp
Set up a new account or request a visit to your office by one of our representatives to discuss our services.